Protocol Number: GR41987
Principal Investigator: Scott Westhouse, D.O.
GR41987 is a study for people who previously participated in and completed the parent studies GR40349 (YOSEMITE) or GR40398 (RHINE). The purpose of this study is to evaluate the effects of long-term use of faricimab on individuals and their diabetic macular edema (DME). Faricimab is an experimental drug, which means the U.S. Food and Drug Administration (FDA) has not approved faricimab for the treatment of DME outside of a clinical study. As of April 2021, more than 4100 subjects have been enrolled in either the completed or ongoing clinical studies of faricimab in subjects with DME, neovascular age-related macular degeneration, and retinal vein occlusion. Of these subjects, more than 2700 subjects have received at least one dose of faricimab.